NDAORAL-20TABLET
Approved
Mar 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORINYL is an oral contraceptive combining mestranol (estrogen) and norethindrone (progestin), approved in 1964. It prevents pregnancy through suppression of ovulation and alteration of cervical mucus and endometrial environment. The product represents a foundational therapy in the oral contraceptive class.
LOE Approaching
LOE-approaching product with moderate competitive pressure (30/100) suggests a mature, consolidating commercial footprint with limited growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Roles on NORINYL are predominantly maintenance-focused rather than growth-oriented, centered on defending market share and managing generic transition. Career advancement on this product is limited; roles typically serve as stepping stones to higher-priority brands.
Product ManagerField Sales Representative
Worked on NORINYL at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.